Physician profile

Robin Tighe

Family · Jacksonville, FL

NPI 1013661214

$254.60

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$193.58

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Corcept Therapeutics $63.94 2023 Korlym
Galderma Laboratories, L.P. $61.02 2022
Abbvie INC. $27.31 2023
Astrazeneca Pharmaceuticals LP $20.94 2023 Breztri
Paratek Pharmaceuticals, INC. $19.16 2023 Nuzyra
Photonicare INC $17.35 2023 Otosight Middle Ear Scope
Amgen INC. $16.18 2023 Otezla, Repatha
Cranial Technologies, INC $15.56 2023 Doc Band
Ibsa Pharma INC. $13.14 2023 Tirosint, Licart

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robin Tighe

$254.60

in general payments reported 2019-2025

Years
2022-2023
Top company
Corcept Therapeutics

https://glasscript.com/doctor/11371973/robin-tighe

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.